Thomas Borgstedte, DO
Family Medicine · la Grange, TXNPI 1295877264
Payments from drug & device makers
Across 285 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$768
- AbbVie$640
- Lilly USA, LLC$466
- GSK$444
- Novartis$302
- Novo Nordisk$256
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,58096%
- Education$1533%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 51 | $768 |
| AbbVie(2 entities) | 40 | $640 |
| Lilly USA, LLC | 25 | $466 |
| GSK | 32 | $444 |
| Novartis | 12 | $302 |
| Novo Nordisk | 23 | $256 |
| Astellas Pharma US Inc | 11 | $243 |
| Boehringer Ingelheim | 12 | $242 |
| Merck | 12 | $210 |
| Pfizer | 12 | $182 |
| Corcept Therapeutics | 5 | $111 |
| AstraZeneca | 5 | $90 |
| Mannkind Corporation | 6 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $80 |
| Johnson & Johnson(2 entities) | 3 | $77 |
| Dexcom, Inc. | 2 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Bayer | 2 | $43 |
| Antares Pharma, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Biowound Solutions, Inc. | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Medtronic | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Exact Sciences | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Optos, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$115
How this compares
$4,747 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $176,769 |
| MounjaroTirzepatide | 157 | $174,785 |
| JardianceEmpagliflozin | 170 | $148,593 |
| OzempicSemaglutide | 131 | $139,525 |
| FarxigaDapagliflozin Propanediol | 79 | $75,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $62,701 |
| FanaptIloperidone | 24 | $56,811 |
| TrulicityDulaglutide | 61 | $53,271 |
| Repatha SureclickEvolocumab | 64 | $46,384 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 124 | $39,955 |
| JanuviaSitagliptin Phosphate | 26 | $39,126 |
| XareltoRivaroxaban | 44 | $27,862 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 103 | $23,130 |
| MyrbetriqMirabegron | 36 | $22,892 |
| LinzessLinaclotide | 29 | $22,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $466 | $228,056218 claims |
| PfizerEliquis, Abrysvo, Premarin | $182 | $223,845372 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $242 | $171,961212 claims |
| Novo NordiskOzempic | $256 | $139,525131 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $444 | $91,689199 claims |
| AstraZenecaFarxiga | $90 | $75,14579 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $13 | $56,81124 claims |
| MerckJanuvia, Belsomra | $210 | $46,16344 claims |
| Johnson & JohnsonXarelto, Invokana | $77 | $34,71755 claims |
| Astellas Pharma US IncMyrbetriq | $243 | $22,89236 claims |
| AbbVieLinzess | $640 | $22,60329 claims |
| NovartisEntresto | $302 | $11,43312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in la Grange
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.